Home Healthcare Biotechnology Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers), By Application (Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 30, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Breast Cancer Liquid Biopsy Market, By Circulating Biomarkers 2022-2034 (USD MILLION/ Units)
    1. Circulating Tumor Cells (CTCs)
    2. Circulating Cell-free DNA (cfDNA)
    3. Extracellular Vesicles (EVs)
    4. Other Circulating Biomarkers
  2. Breast Cancer Liquid Biopsy Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Early Detection/Screening
    2. Diagnosis
    3. Treatment Selection
    4. Monitoring
  3. Regional Breast Cancer Liquid Biopsy Market
    1. North America
      1. North America Breast Cancer Liquid Biopsy Market By Circulating Biomarkers 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
      2. North America Breast Cancer Liquid Biopsy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Early Detection/Screening
        2. Diagnosis
        3. Treatment Selection
        4. Monitoring
      3. U.S.
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      4. Canada
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
    2. Europe
      1. Europe Breast Cancer Liquid Biopsy Market By Circulating Biomarkers 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
      2. Europe Breast Cancer Liquid Biopsy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Early Detection/Screening
        2. Diagnosis
        3. Treatment Selection
        4. Monitoring
      3. U.K.
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      4. Germany
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      5. France
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      6. Spain
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      7. Italy
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      8. Russia
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      9. Nordic
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      10. Benelux
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      11. Rest of Europe
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
    3. APAC
      1. APAC Breast Cancer Liquid Biopsy Market By Circulating Biomarkers 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
      2. APAC Breast Cancer Liquid Biopsy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Early Detection/Screening
        2. Diagnosis
        3. Treatment Selection
        4. Monitoring
      3. China
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      4. Korea
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      5. Japan
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      6. India
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      7. Australia
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      8. Taiwan
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      9. South East Asia
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      10. Rest of Asia-Pacific
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
    4. Middle East and Africa
      1. Middle East and Africa Breast Cancer Liquid Biopsy Market By Circulating Biomarkers 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
      2. Middle East and Africa Breast Cancer Liquid Biopsy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Early Detection/Screening
        2. Diagnosis
        3. Treatment Selection
        4. Monitoring
      3. UAE
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      4. Turkey
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      5. Saudi Arabia
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      6. South Africa
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      7. Egypt
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      8. Nigeria
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      9. Rest of MEA
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
    5. LATAM
      1. LATAM Breast Cancer Liquid Biopsy Market By Circulating Biomarkers 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
      2. LATAM Breast Cancer Liquid Biopsy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Early Detection/Screening
        2. Diagnosis
        3. Treatment Selection
        4. Monitoring
      3. Brazil
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      4. Mexico
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      5. Argentina
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      6. Chile
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      7. Colombia
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
      8. Rest of LATAM
        1. Circulating Tumor Cells (CTCs)
        2. Circulating Cell-free DNA (cfDNA)
        3. Extracellular Vesicles (EVs)
        4. Other Circulating Biomarkers
        5. Early Detection/Screening
        6. Diagnosis
        7. Treatment Selection
        8. Monitoring
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.